Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

When the FRAX(®) test is applied to controlled clinical trials.

Fiore CE, Gaudio A.

Clin Cases Miner Bone Metab. 2012 Sep;9(3):135-7. Epub 2012 Dec 20.

2.

[Osteoporosis - whom to treat? The importance of FRAX® in Switzerland].

Lippuner K.

Ther Umsch. 2012 Mar;69(3):207-13. doi: 10.1024/0040-5930/a000275. German.

PMID:
22403115
3.

Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.

Siris ES, Baim S, Nattiv A.

Postgrad Med. 2010 Jan;122(1):82-90. doi: 10.3810/pgm.2010.01.2102. Review.

PMID:
20107292
4.

FRAX and the assessment of fracture probability in men and women from the UK.

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E.

Osteoporos Int. 2008 Apr;19(4):385-97. doi: 10.1007/s00198-007-0543-5. Epub 2008 Feb 22.

5.

Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos.

Fraser LA, Langsetmo L, Berger C, Ioannidis G, Goltzman D, Adachi JD, Papaioannou A, Josse R, Kovacs CS, Olszynski WP, Towheed T, Hanley DA, Kaiser SM, Prior J, Jamal S, Kreiger N, Brown JP, Johansson H, Oden A, McCloskey E, Kanis JA, Leslie WD; CaMos Research Group.

Osteoporos Int. 2011 Mar;22(3):829-37. doi: 10.1007/s00198-010-1465-1. Epub 2010 Dec 16.

PMID:
21161508
6.
7.

Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment.

Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA, Adachi JD, Johansson H, Oden A, McCloskey E, Kanis JA.

Osteoporos Int. 2011 Mar;22(3):817-27. doi: 10.1007/s00198-010-1464-2. Epub 2010 Dec 16.

PMID:
21161509
8.

Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.

Silverman SL, Komm BS, Mirkin S.

Maturitas. 2014 Nov;79(3):241-7. doi: 10.1016/j.maturitas.2014.07.007. Epub 2014 Jul 16.

PMID:
25124532
9.

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group.

Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1. Epub 2008 Aug 28. Erratum in: Osteoporos Int. 2009 Mar;20(3):499-502.

PMID:
18751937
10.

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

Kanis JA, Johansson H, Oden A, McCloskey EV.

Osteoporos Int. 2011 Aug;22(8):2347-55. doi: 10.1007/s00198-010-1474-0. Epub 2011 Feb 2. Erratum in: Osteoporos Int. 2011 Aug;22(8):2357-8.

PMID:
21287148
11.

Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.

Borgström F, Ström O, Kleman M, McCloskey E, Johansson H, Odén A, Kanis JA.

Osteoporos Int. 2011 Mar;22(3):955-65. doi: 10.1007/s00198-010-1291-5. Epub 2010 Jun 8.

PMID:
20532482
12.

Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.

Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR.

J Bone Miner Res. 2012 Aug;27(8):1804-10. doi: 10.1002/jbmr.1625.

13.

Fracture risk prediction using FRAX®: a 10-year follow-up survey of the Japanese Population-Based Osteoporosis (JPOS) Cohort Study.

Tamaki J, Iki M, Kadowaki E, Sato Y, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H.

Osteoporos Int. 2011 Dec;22(12):3037-45. doi: 10.1007/s00198-011-1537-x. Epub 2011 Jan 29.

PMID:
21279504
14.

Spine-hip T-score difference predicts major osteoporotic fracture risk independent of FRAX(®): a population-based report from CAMOS.

Leslie WD, Kovacs CS, Olszynski WP, Towheed T, Kaiser SM, Prior JC, Josse RG, Jamal SA, Kreiger N, Goltzman D; CaMos Research Group.

J Clin Densitom. 2011 Jul-Sep;14(3):286-93. doi: 10.1016/j.jocd.2011.04.011. Epub 2011 Jul 1.

PMID:
21723768
15.

Preventing osteoporotic fractures in older people.

McCloskey E.

Practitioner. 2011 Jan;255(1736):19-22, 2-3.

PMID:
21370710
16.

A comparative study of using non-hip bone density inputs with FRAX®.

Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA; Manitoba Bone Density Program.

Osteoporos Int. 2012 Mar;23(3):853-60. doi: 10.1007/s00198-011-1814-8. Epub 2011 Oct 19.

PMID:
22008881
17.

Smoking is a predictor of worse trabecular mechanical performance in hip fragility fracture patients.

Rodrigues AM, Caetano-Lopes J, Vale AC, Aleixo I, Pena AS, Faustino A, Sepriano A, Polido-Pereira J, Vieira-Sousa E, Lucas R, Romeu JC, Monteiro J, Vaz MF, Fonseca JE, Canhão H.

J Bone Miner Metab. 2012 Nov;30(6):692-9. doi: 10.1007/s00774-012-0370-4. Epub 2012 Aug 14.

PMID:
22886402
18.

High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice.

Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA; Manitoba Bone Density Program.

Osteoporos Int. 2012 Jan;23(1):391-7. doi: 10.1007/s00198-011-1592-3. Epub 2011 Mar 2.

PMID:
21365460
19.

Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool.

Trémollieres FA, Pouillès JM, Drewniak N, Laparra J, Ribot CA, Dargent-Molina P.

J Bone Miner Res. 2010 May;25(5):1002-9. doi: 10.1002/jbmr.12.

20.

A FRAX® model for the assessment of fracture probability in Belgium.

Johansson H, Kanis JA, McCloskey EV, Odén A, Devogelaer JP, Kaufman JM, Neuprez A, Hiligsmann M, Bruyere O, Reginster JY.

Osteoporos Int. 2011 Feb;22(2):453-61. doi: 10.1007/s00198-010-1218-1. Epub 2010 Mar 30.

PMID:
20352409
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk